Table 2.
N | 5-yr OS % | OS HR (95% CI, p = ) | 5-yr PFS % | PFS HR (95% CI, p = ) | |
---|---|---|---|---|---|
Entire Cohort | 85 | 22.2 | N/A | 15.1 | — |
Age | |||||
<50 | 38 | 27.9 | Ref. | 15.8 | Ref. |
50+ | 47 | 18.0 | 1.36 (0.37–2.21, p = 0.22) | 12.1 | 1.33 (0.84–2.12, p = 0.23) |
Sex | |||||
Male | 61 | 22.6 | Ref. | 16.1 | Ref. |
Female | 24 | 20.8 | 1.26 (0.75–2.11, p = 0.38) | 12.5 | 1.27 (0.77–2.11, p = 0.34) |
Race | |||||
White | 76 | 22.1 | — | 16.9 | — |
Unknown | 4 | 0 | — | 0 | — |
Other | 3 | 0 | — | 0 | — |
Black or African American | 1 | 0 | — | 0 | — |
Asian Chinese | 1 | 100 | — | 0 | — |
Prior Auto SCT(s) | |||||
0 | 4 | 50.0 | Ref. | 0.75 | Ref. |
1 | 63 | 24.4 | 2.62 (0.63–10.83, p = 0.18) | 0.14 | 2.49 (0.76–8.16, p = 0.13) |
2 | 18 | 0 | 5.68 (1.28–25.22, p = 0.02*) | 0 | 4.86 (1.36–17.39, p = 0.02*) |
Years MM Dx to Allo SCT | |||||
0–2 | 20 | 30.0 | Ref. | 18.7 | Ref. |
2–5 | 48 | 19.8 | 1.24 (0.68–2.23, p = 0.47) | 12.9 | 1.39 (0.78–2.48, p = 0.27) |
5+ | 17 | 18.1 | 1.28 (0.61–2.66, p = 0.51) | 9.6 | 1.44 (0.71–2.93, p = 0.31) |
Years Auto SCT1 to Allo SCT (N = 81) | |||||
0–2 years | 45 | 20.0 | Ref. | 10.5 | Ref. |
2+ years | 36 | 18.4 | 1.11 (0.68–1.82, p = 0.67) | 10.8 | 1.15 (0.72–1.84, p = 0.57) |
Auto SCT1 Response at Day 100 (N = 70) | |||||
CR | 30 | 29.2 | Ref. | 19.1 | Ref. |
VGPR | 10 | 30.0 | 0.93 (0.39–2.18, p = 0.86) | 20.0 | 0.79 (0.35–1.75, p = 0.55) |
PR | 25 | 12.0 | 1.96 (1.08–3.56, p = 0.03*) | 8.5 | 1.30 (0.73–2.31, p = 0.36) |
Progression | 5 | 20.0 | 1.40 (0.39–2.18, p = 0.86) | 0 | 1.31 (0.50–3.45, p = 0.58) |
Years Auto SCT2 to Allo SCT (N = 18) | |||||
0–2 years | 14 | 0 | Ref. | 0 | Ref. |
2+ years | 4 | 25 | 0.64 (0.18–2.27, p = 0.49) | 25 | 0.40 (0.11–1.44, p = 0.16) |
Auto SCT2 Response at Day 100 (N = 10) | |||||
CR | 1 | 0 | Ref. | 100 | — |
VGPR | 1 | 0 | 0.71 (0.04–12.31, p = 0.82) | 0 | — |
PR | 6 | 33.3 | 0.33 (0.03–3.52, p = 0.36) | 0 | — |
Progression | 2 | 0 | 0.49 (0.03–7.10, p = 0.60) | 0 | — |
Allo Date | |||||
2000–2010 | 46 | 23.9 | Ref. | 14.6 | Ref. |
2011- | 39 | 20.3 | 1.32 (0.82–2.15, p = 0.26) | 16.0 | 1.27 (0.79–2.02, p = 0.32) |
Response Status Going Into Allo SCT (N = 78) | |||||
CR | 14 | 42.9 | Ref. | 35.9 | Ref. |
VGPR | 11 | 11.3 | 1.94 (0.74–5.07, p = 0.18) | 9.1 | 2.41 (0.93–6.23, p = 0.06) |
PR | 22 | 21.2 | 1.81 (0.81–4.02, p = 0.15) | 5.9 | 2.13 (0.93–4.88, p = 0.07) |
Stable disease | 7 | 28.6 | 1.35 (0.45–4.04, p = 0.59) | 28.6 | 1.58 (0.54–4.62, p = 0.40) |
Progression | 24 | 10.4 | 3.39 (1.54–7.46, p = <0.01*) | 4.2 | 4.39 (1.93–9.98, p = <0.01*) |
Cytogenetic Risk (N = 80) | |||||
Standard | 53 | 22.1 | Ref. | 16.9 | Ref. |
High risk* | 27 | 11.5 | 1.10 (0.66–1.82, p = 0.72) | 10.2 | 1.35 (0.79–2.28, p = 0.26) |
Transplant Intensity | |||||
MA | 47 | 28.3 | Ref. | 19.8 | Ref. |
RIC | 26 | 20.1 | 0.93 (0.54–1.60, p = 0.79) | 13.8 | 0.85 (0.50–1.45, p = 0.56) |
NMA | 12 | 8.3 | 1.18 (0.60–2.30, p = 0.63) | 0 | 1.22 (0.63–2.37, p = 0.55) |
Transplant course: | |||||
Standalone MA allo SCT | 47 | 28.3 | Ref. | 19.8 | Ref. |
Standalone RIC allo SCT | 15 | 14.4 | 1.20 (0.63–2.27, p = 0.59) | 7.2 | 1.04 (0.56–1.96, p = 0.90) |
Standalone NMA allo SCT | 6 | 0 | 1.22 (0.50–2.93, p = 0.66) | 0 | 1.36 (0.57–3.23, p = 0.49) |
Upfront auto SCT to RIC allo SCT | 3 | 33.3 | 0.78 (0.24–2.55, p = 0.68) | 0 | 0.86 (0.23–2.80, p = 0.80) |
Auto SCT to RIC (or NMA) allo SCT for relapse | 14 | 21.4 | 0.84 (0.42–1.65, p = 0.60) | 19.1 | 0.78 (0.40–1.53, p = 0.47) |
Acute GVHD | |||||
Present | 50 | 23.6 | Ref. | 11.7 | Ref. |
Absent | 35 | 18.9 | 0.91 (0.56–1.49, p = 0.71) | 19.9 | 0.93 (0.58–1.49, p = 0.75) |
Chronic GVHD | |||||
Present | 38 | 23.1 | Ref. | 16.2 | Ref. |
Absent | 47 | 18.0 | 1.65 (1.02–2.71, p = 0.04) | 14.2 | 1.34 (0.84–2.13, p = 0.22) |
Lines of Therapy Before Allo SCT | |||||
1–3 | 21 | 23.8 | Ref. | 12.9 | Ref. |
4–6 | 48 | 25.7 | 1.03 (0.57–1.81, p = 0.91) | 19.3 | 1.05 (0.59–1.85, p = 0.87) |
7+ | 16 | 0 | 1.50 (0.71–3.16, p = 0.28) | 0 | 1.97 (0.98–3.97, p = 0.06) |
Donor Type (N = 84) | |||||
PBSC Related | 50 | 21.0 | Ref. | 16.3 | Ref. |
PBSC Unrelated | 32 | 22.3 | 0.89 (0.54–1.49, p = 0.67) | 14.9 | 0.94 (0.58–1.53, p = 0.82) |
Single UC Unrelated | 1 | 0 | 1.01 (0.14–7.41, p = 0.99) | 0 | 1.02 (0.14–7.57, p = 0.97) |
Double UC Unrelated | 1 | 0 | 9.6 (1.19–77.46, p = 0.04*) | 0 | 8.61 (1.08–68.50, p = 0.04*) |
HR Hazard Ratio.
Ref. Reference variable for hazard ratio generation.
Auto SCT autologous stem cell transplant.
Allo SCT allogeneic stem cell transplant.
CR complete response.
VGPR very good partial response.
PR partial response.
MA myeloablative.
RIC reduced-intensity chemotherapy.
NMA nonmyeloablative.
GVHD graft-versus host disease.
PBSC peripheral blood stem cell.
UC umbilical cord.
*p < 0.05.
Bold entries denote statistically significant p values.